The 'psilocybin live-in-the-moment' finding draws a published mechanistic caveat separating acute network effects from durable clinical change.

A recent study found that psilocybin changes how brain networks communicate in ways linked to being more present and in the moment. But scientists are likely to quickly publish responses pointing out that seeing something happen in the brain right after taking a drug doesn't prove the person stays better weeks or months later. This kind of critique is a normal, healthy part of science.

Acute neuroimaging effects don't equal lasting therapeutic change. Anchored to today's specific psilocybin acute-network finding; critics reliably publish durability caveats within weeks.